NCM
EDSA icon

Nantahala Capital Management’s Edesa Biotech EDSA Stock Holding History

Nantahala Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-625,000
Closed -$888K – 160
2025
Q4 		$888K Hold
625,000
– – 0.03% 139
2025
Q3 		$1.54M Hold
625,000
– – 0.05% 136
2025
Q2 		$1.27M Hold
625,000
– – 0.05% 130
2025
Q1 		$1.52M Buy
+625,000
New +$1.35M 0.06% 113

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Nantahala Capital Management's EDSA Position: Q1 2026 in Review

Nantahala Capital Management sold out of Edesa Biotech (EDSA) in Q1 2026, closing a stake of 625,000 shares — an estimated $888K sold.

Nantahala Capital Management first reported a position in EDSA in Q1 2025 and held it in 4 quarters. The position peaked at $1.54M in Q3 2025. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

  • Nantahala Capital Management reported no remaining Edesa Biotech position as of Q1 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 625,000 Edesa Biotech shares in Q1 2026, an estimated $888K.
  • Nantahala Capital Management first reported a position in Edesa Biotech in Q1 2025 and held it in 4 quarters.
  • Nantahala Capital Management's Edesa Biotech position peaked at $1.54M in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.